|
January 16, 2004
Appointments of Vice Presidents of Business Development and Human Resources.
Neurochem expands Management Team.
- Neurochem, Inc. (NASDAQ: NRMX, TSX: NRM) - announced today the appointment of two new vice presidents
to further support its professional management team as the Company approaches commercialization of its
innovative product candidates. Ms. Christine Lennon, becomes Vice President, Business Development, at
Neurochem, and Ms. Judith Paquin assumes the position of Vice President, Human Resources.
"Companies are made up of individuals and at Neurochem it is the quality of our personnel and
management team that is a key determinant in our success," said Dr. Francesco Bellini, Chairman
and CEO of Neurochem. "I am therefore very pleased that Neurochem has been able to attract people
of the professional calibre and extensive experience of Ms. Lennon and Ms. Paquin. Their skills
will be invaluable as we move forward. Neurochem is entering a period of intense growth with
highly qualified management, a promising pipeline and solid financing," he concluded.
Christine Lennon brings more than fifteen years experience in the pharmaceutical sector to
Neurochem. Before joining the Company, Ms. Lennon held the position of Venture Advisor for the
Biotechnology and Life Sciences investment sector of CDP Capital - Technology Ventures, part of
Canada's largest pension fund. Immediately prior to that she spent seven years as part of the
senior management team within BioChem Pharma Inc. (now part of Shire Pharmaceuticals), Canada's then
leading biopharmaceutical company, where she began as Director, Investor Relations, in May 1994. In
1996, she was promoted to Vice President, Corporate Communications and Investor Relations, and
was promoted again in 1999 to Vice President, Global Commercial Development - Oncology. Ms. Lennon
began her career at Sandoz Canada Inc. (now Novartis), where she held many positions of increasing
responsibility in sales and marketing. Ms. Lennon holds a Masters of Business Administration and
a Bachelor's Degree in Science (Honors) , both from McGill University.
Judith Paquin's experience in human resources management extends over a fifteen-year period and
was gained within the high tech and telecommunications industry as well as in the research-based
pharmaceutical sector. Ms. Paquin has held varied positions of increasing responsibility in human
resources, communications and labour relations for different companies such as Bell Canada, Nortel
Networks and Beltron Information Technology. Prior to joining Neurochem, she worked for the
Canadian subsidiary of Schering-Plough Pharmaceuticals (Schering Canada Inc.) where she accepted
a position of Human Resources Manager in 1995. Then in 1997, she was promoted to the position of
Vice President, Human Resources. Ms. Paquin holds a Bachelor's Degree in Business Administration
from l'École des Hautes Etudes Commerciales (HEC), and is an accredited member of l'Ordre
des Professionels en Ressources humaines du Québec.
About Neurochem
Neurochem is focused on the development and commercialization of innovative therapeutics for
neurological disorders. The Company's staged pipeline of proprietary, disease-modifying, oral products
addresses critical unmet medical needs. Fibrillex™, designated an orphan drug, is in a Phase
II/III clinical trial for AA amyloidosis. Alzhemed™ has completed a Phase II clinical trial for
the treatment of Alzheimer's Disease. Cerebril™ is in a Phase II trial for the prevention of
hemorrhagic stroke caused by cerebral amyloid angiopathy. For additional information on Neurochem,
please visit our website at: (www.neurochem.com).
All of the statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, are forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown. Some examples of known risks are: the impact of general economic conditions, general conditions in the pharmaceutical industry, changes in the regulatory environment in the jurisdictions in which Neurochem does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation or otherwise. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements.
For further Information, please contact:
Dr. Lise Hébert
Vice President, Corporate Communications
lhebert@neurochem.com
275 Armand-Frappier
Laval (Quebec)
H7V 4A7
Tel: (450) 680-4500
Fax: (450) 680-4501
|
